MHC class I+ and class I(-)HPV16-associated tumours expressing the E7 oncoprotein do not cross-react in immunization/challenge experiments

0191666 - UMG-J 20033177 RIV CZ eng J - Článek v odborném periodiku
Šímová, Jana - Mikyšková, Romana - Vonka, V. - Bieblová, Jana - Bubeník, Jan - Jandlová, Táňa
MHC class I+ and class I(-)HPV16-associated tumours expressing the E7 oncoprotein do not cross-react in immunization/challenge experiments.
Folia Biologica. Roč. 2003, č. 49 (2003), s. 230-234. ISSN 0015-5500. E-ISSN 0015-5500
Výzkumný záměr: CEZ:AV0Z5052915
Klíčová slova: HPV 16 * MHC class I expression * tumour vaccines
Kód oboru RIV: EB - Genetika a molekulární biologie
Impakt faktor: 0.527, rok: 2003

It has been demonstrated repeatedly that a high proportion of tumours derived from MHC class I+ precursors Are MHC class I-. Since a major task in immunotherapy strategies for treatment of malignancies is to develop polyvalent tumour vaccines efficient against a broad spectrum of tumours, we have examined whether MHC class 11 cell-based tumour vaccines can cross-protect against homologous MHC class I- tumour challenge and vice versa. For these purposes, we have used two oncogenic cell lines induced independently by co-transfection of murine H-2(b) cells with E6/E7 HPV16 and activated Ha-ras oncogenes, the tumours TC-1 (MHC class 11, HPV16 E7(+)) and MK16/1/IIIABC (MHC class I-, HPV16 E7(+)). Surprisingly, it was found that these two tumours do not cross-react, although both of them contain the crucial HPV16-coded tumour rejection antigen E7. Preimmunization with the MHC class I+ tumour did not protect against a subsequent challenge with the MHC class I- tumour and vice versa; however, immunization with the TC-1 tumour could protect syngeneic mice against the TC-1 tumour challenge and, similarly, immunization with the MK16/1/IIIABC tumour could protect mice against the MK16/1/IIIABC tumour challenge. If this finding can also be confirmed as a more general phenomenon with other MHC class I+ and class P tumours, it could have serious implications for design of immunotherapeutic vaccines and protocols.
Trvalý link: http://hdl.handle.net/11104/0087404